...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of stroke and cerebrovascular diseases: The official journal of National Stroke Association >Prognostic value of plasma HMGB1 in ischemic stroke patients with cerebral ischemia-reperfusion injury after intravenous thrombolysis
【24h】

Prognostic value of plasma HMGB1 in ischemic stroke patients with cerebral ischemia-reperfusion injury after intravenous thrombolysis

机译：静脉溶栓后脑缺血再灌注损伤缺血性脑卒中患者血浆HMGB1的预后价值

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: To investigate the value of plasma high mobility group box protein 1 (HMGB1) in evaluating the prognosis of cerebral ischemia-reperfusion injury (CIRI) in ischemic stroke patients. Methods: 132 ischemic stroke patients were recruited. Before and after thrombolytic therapy at 2 h, 6 h, 12 h, 24 h, and 36 h, the Glasgow Coma Scale (GCS) and National Institutes of Health Stroke Scale (NIHSS) were recorded. The Modified Rankin scale (mRS) was used to assess the prognosis at 3 months. Results: The NIHSS score, GCS score and plasma HMGB1 level peaked at 6 h after thrombolytic therapy, and plasma HMGB1 level was positively correlated with infarct volume and NIHSS score, and negatively correlated with GCS score. Plasma HMGB1 level at 6 h had the highest value in identifying patients with poor unfavorable functional outcome after 3 months, with a sensitivity of 86.8% and a specificity of 74.0%. Logistic regression results showed that plasma HMGB1 had a strong association with unfavorable functional outcome [odds ratio (OR) =1.621, P<0.001]. After adjusting for infarct volume and NIHSS score did not attenuate the association (OR=1.381, P=0.005). Finally, we found that plasma HMGB1 at 6 h had the highest value in identifying patients with non-survival after 3 months (chi(2)=28.655, P<0.001). Logistic regression results showed that plasma HMGB1 had a strong association with non-survival (OR=2.315, P<0.001). After adjusting for infarct volume and NIHSS score did not attenuate the association (OR=2.013, P<0.001). Conclusion: Plasma HMGB1 exerts a good predictive value for CIRI in ischemic stroke patients, and its increased expression is correlated with worse prognosis. (c) 2020 Elsevier Inc. All rights reserved.
机译：背景：探讨血浆高迁移率族蛋白1（HMGB1）在评价缺血性脑卒中患者脑缺血再灌注损伤（CIRI）预后中的价值。方法：纳入132例缺血性脑卒中患者。在溶栓治疗2小时、6小时、12小时、24小时和36小时前后，记录格拉斯哥昏迷量表（GCS）和美国国立卫生研究院卒中量表（NIHSS）。采用改良Rankin量表（mRS）评估3个月后的预后。结果：NIHSS评分、GCS评分和血浆HMGB1水平在溶栓治疗后6h达到峰值，血浆HMGB1水平与梗死体积和NIHSS评分呈正相关，与GCS评分呈负相关。6小时时的血浆HMGB1水平在识别3个月后功能不良患者方面具有最高的价值，其敏感性为86.8%，特异性为74.0%。Logistic回归分析结果显示，血浆HMGB1与不良的功能结果密切相关[优势比（OR）=1.621，P<0.001]。校正梗死体积和NIHSS评分后，这种相关性并未减弱（OR=1.381，P=0.005）。最后，我们发现6小时时的血浆HMGB1在识别3个月后无存活患者方面具有最高值（chi（2）=28.655，P<0.001）。Logistic回归分析结果显示，血浆HMGB1与非存活率有很强的相关性（OR=2.315，P<0.001）。校正梗死体积和NIHSS评分后，这种相关性并未减弱（OR=2.013，P<0.001）。结论：血浆HMGB1对缺血性脑卒中患者的CIRI具有良好的预测价值，其表达增加与预后不良相关。（c） 2020爱思唯尔公司版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号